Celea Therapeutics
deupirfenidone
idiopathic pulmonary fibrosis
Countdown
86days
FDA decision · ~ Sep 30, 2026 estimated
What's at stake
The FDA's approval decision on deupirfenidone for idiopathic pulmonary fibrosis is due ~ Sep 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 10h ago
“December 2025: Announced successful completion of the End-of-Phase 2 meeting with the FDA regarding development of deupirfenidone for the treatment of IPF and shared plans for pivotal, Phase 3 head-to-head SURPASS-IPF trial evaluating super”